Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase by a stavudine analogue, 4′-ethynyl stavudine triphosphate

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 6, 2008, Pages 2035-2042

  Yang, Guangwei ^a   Wang, Jimin ^a   Cheng, Yao ^a   Dutschman, Ginger E ^a   Tanaka, Hiromichi ^b   Baba, Masanori ^c   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHOWA UNIVERSITY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEHYDRO 3' DEOXY 4' ETHYNYLTHYMIDINE; 4' ETHYNYLSTAVUDINE TRIPHOSPHATE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ARTICLE; BINDING AFFINITY; COMPUTER MODEL; DISSOCIATION CONSTANT; DNA REPLICATION; DNA TEMPLATE; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; HYDROPHOBICITY; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; RNA BINDING; STEADY STATE; VIRUS INHIBITION;

ANTI-HIV AGENTS; BASE SEQUENCE; CRYSTALLIZATION; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; POLYPHOSPHATES; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44449119875     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00083-08     Document Type: Article

References (42)

1. Back, N. K., M. Nijhuis, W. Keulen, C. A. Boucher, B. O. Oude Essink, A. B. van Kuilenburg, A. H. van Gennip, and B. Berkhout. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
2. Boyer, P. L., and S. H. Hughes. 1995. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 39:1624-1628.
3. Chao, S. F., V. L. Chan, P. Juranka, A. H. Kaplan, R. Swanstrom, and C. A. Hutchison III. 1995. Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res. 23:803-810.
4. Chen, C. H., and Y. C. Cheng. 1989. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J. Biol. Chem. 264:11934-11937.
5. Chen, C. H., M. Vazquez-Padua, and Y. C. Cheng. 1991. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol. Pharmacol. 39:625-628.
6. Dutschman, G. E., S. P. Grill, E. A. Gullen, K. Haraguchi, S. Takeda, H. Tanaka, M. Baba, and Y. C. Cheng. 2004. Novel 4′-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob. Agents Chemother. 48:1640-1646.
7. Feng, J. Y., and K. S. Anderson. 1999. Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase. Biochemistry 38:55-63.
8. Feng, J. Y., and K. S. Anderson. 1999. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry 38:9440-9448.
9. Hamamoto, Y., H. Nakashima, T. Matsui, A. Matsuda, T. Ueda, and N. Yamamoto. 1987. Inhibitory effect of 2′,3′-didehydro-2′, 3′-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus. Antimicrob. Agents Chemother. 31:907-910.
10. Haraguchi, K., S. Takeda, H. Tanaka, T. Nitanda, M. Baba, G. E. Dutschman, and Y. C. Cheng. 2003. Synthesis of a highly active new anti-HIV agent 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine. Bioorg. Med. Chem. Lett. 13:3775-3777.
11. Hsu, C. H., R. Hu, G. E. Dutschman, G. Yang, P. Krishnan, H. Tanaka, M. Baba, and Y. C. Cheng. 2007. Comparison of the phosphorylation of 4′-ethynyl 2′,3′-dihydro-3′-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs. Antimicrob. Agents Chemother. 51:1687-1693.
12. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
13. Jamburuthugoda, V. K., D. Guo, J. E. Wedekind, and B. Kim. 2005. Kinetic evidence for interaction of human immunodeficiency virus type 1 reverse transcriptase with the 3′-OH of the incoming dTTP substrate. Biochemistry 44:10635-10643.
14. Johnson, K. A. 1993. Conformational coupling in DNA polymerase fidelity. Annu. Rev. Biochem. 62:685-713.
15. Johnson, K. J., J. Varani, and J. E. Smolen. 1992. Neutrophil activation and function in health and disease. Immunol. Ser. 57:1-46.
16. Jones, T. A., J. Y. Zou, S. W. Cowan, and M. Kjeldgaard. 1991. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47:110-119.
17. Kati, W. M., K. A. Johnson, L. F. Jerva, and K. S. Anderson. 1992. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 267:25988-25997.
18. Kerr, S. G., and K. S. Anderson. 1997. Pre-steady-state kinetic characterization of wild type and 3′-azido-3′-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance. Biochemistry 36:14064-14070.
19. Kodama, E. I., S. Kohgo, K. Kitano, H. Machida, H. Gatanaga, S. Shigeta, M. Matsuoka, H. Ohrui, and H. Mitsuya. 2001. 4′-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob. Agents Chemother. 45:1539-1546.
20. Krishnan, P., J. Y. Liou, and Y. C. Cheng. 2002. Phosphorylation of pyrimidine L-deoxynucleoside analog diphosphates. Kinetics of phosphorylation and dephosphorylation of nucleoside analog diphosphates and triphosphates by 3-phosphoglycerate kinase. J. Biol. Chem. 277:31593-31600.
21. Lin, T. S., R. F. Schinazi, M. S. Chen, E. Kinney-Thomas, and W. H. Prusoff. 1987. Antiviral activity of 2′,3′-dideoxycytidin- 2′-ene (2′,3′-dideoxy-2′,3′-didehydrocytidine) against human immunodeficiency virus in vitro. Biochem. Pharmacol. 36:311-316.
22. Lin, T. S., R. F. Schinazi, and W. H. Prusoff. 1987. Potent and selective in vitro activity of 3′-deoxythymidin-2′-ene (3′-deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus. Biochem. Pharmacol. 36:2713-2718.
23. Medina, D. J., C. H. Tsai, G. D. Hsiung, and Y. C. Cheng. 1994. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob. Agents Chemother. 38:1824-1828.
24. Mitsuya, H., R. Yarchoan, and S. Broder. 1990. Molecular targets for AIDS therapy. Science 249:1533-1544.
25. Murakami, E., A. S. Ray, R. F. Schinazi, and K. S. Anderson. 2004. Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of D- and L-D4FC-TP. Antivir. Res. 62:57-64.
26. Nakata, H., M. Amano, Y. Koh, E. Kodama, G. Yang, C. M. Bailey, S. Kohgo, H. Hayakawa, M. Matsuoka, K. S. Anderson, Y. C. Cheng, and H. Mitsuya. 2007. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4′-ethynyl-2-fluoro-2′-deoxyadenosine. Antimicrob. Agents Chemother. 51:2701-2708.
27. Nitanda, T., X. Wang, H. Kumamoto, K. Haraguchi, H. Tanaka, Y. C. Cheng, and M. Baba. 2005. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2′,3′-didehydro-3′-deoxy-4′- ethynylthymidine in vitro. Antimicrob. Agents Chemother. 49:3355-3360.
28. Ohrui, H., S. Kohgo, K. Kitano, S. Sakata, E. Kodama, K. Yoshimura, M. Matsuoka, S. Shigeta, and H. Mitsuya. 2000. Syntheses of 4′-C-ethynyl-beta-D-arabino- and 4′-C-ethynyl-2′-deoxy-beta-D- ribo-pentofuranosylpyrimidines and -purines and evaluation of their anti-HIV activity. J. Med. Chem. 43:4516-4525.
29. Ostermann, N., D. Segura-Pena, C. Meier, T. Veit, C. Monnerjahn, M. Konrad, and A. Lavie. 2003. Structures of human thymidylate kinase in complex with prodrugs: implications for the structure-based design of novel compounds. Biochemistry 42:2568-2577.
30. Paintsil, E., G. E. Dutschman, R. Hu, S. P. Grill, W. Lam, M. Baba, H. Tanaka, and Y. C. Cheng. 2007. Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2′,3′-didehydro- 3′-deoxy4′-ethynylthymidine, a novel thymidine analog. Antimicrob. Agents Chemother. 51:3870-3879.
31. Ray, A. S., Z. Yang, J. Shi, A. Hobbs, R. F. Schinazi, C. K. Chu, and K. S. Anderson. 2002. Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate. Biochemistry 41:5150-5162.
32. Sawaya, M. R., R. Prasad, S. H. Wilson, J. Kraut, and H. Pelletier. 1997. Crystal structures of human DNA polymerase beta complexed with gapped and nicked DNA: evidence for an induced fit mechanism. Biochemistry 36:11205-11215.
33. Schinazi, R. F., R. M. Lloyd, Jr., M. H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
34. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, et al. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
35. Selmi, B., J. Boretto, J. M. Navarro, J. Sire, S. Longhi, C. Guerreiro, L. Mulard, S. Sarfati, and B. Canard. 2001. The valine-to-threonine 75 substitution in human immunodeficiency virus type 1 reverse transcriptase and its relation with stavudine resistance. J. Biol. Chem. 276:13965-13974.
36. Siddiqui, M. A., S. H. Hughes, P. L. Boyer, H. Mitsuya, Q. N. Van, C. George, S. G. Sarafinanos, and V. E. Marquez. 2004. A 4′-C-ethynyl- 2′,3′-dideoxynucleoside analogue highlights the role of the 3′-OH in anti-HIV active 4′-C-ethynyl-2′-deoxy nucleosides. J. Med. Chem. 47:5041-5048.
37. Thrall, S. H., R. Krebs, B. M. Wohrl, L. Cellai, R. S. Goody, and T. Restle. 1998. Pre-steady-state kinetic characterization of RNA-primed initiation of transcription by HIV-1 reverse transcriptase and analysis of the transition to a processive DNA-primed polymerization mode. Biochemistry 37:13349-13358.
38. Vaccaro, J. A., K. M. Parnell, S. A. Terezakis, and K. S. Anderson. 2000. Mechanism of inhibition of the human immunodeficiency virus type 1 reverse transcriptase by d4TTP: an equivalent incorporation efficiency relative to the natural substrate dTTP. Antimicrob. Agents Chemother. 44:217-221.
39. Wakefield, J. K., S. A. Jablonski, and C. D. Morrow. 1992. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J. Virol. 66:6806-6812.
40. Wohrl, B. M., R. Krebs, R. S. Goody, and T. Restle. 1999. Refined model for primer/template binding by HIV-1 reverse transcriptase: pre-steady-state kinetic analyses of primer/template binding and nucleotide incorporation events distinguish between different binding modes depending on the nature of the nucleic acid substrate. J. Mol. Biol. 292:333-344.
41. Yang, G., G. E. Dutschman, C. J. Wang, H. Tanaka, M. Baba, K. S. Anderson, and Y. C. Cheng. 2007. Highly selective action of triphosphate metabolite of 4′-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT. Antivir. Res. 73:185-191.
42. Zhang, H., C. Rhee, A. Bebenek, J. W. Drake, J. Wang, and W. Konigsberg. 2006. The L561A substitution in the nascent base-pair binding pocket of RB69 DNA polymerase reduces base discrimination. Biochemistry 45:2211-2220.